277
1. Absoud M, Greenberg BM, Lim M, Lotze T, Thomas T, Deiva K. Pediatric transverse myelitis. Neurology. 2016;87(9 Suppl 2):S46-S52. doi:10.1212/WNL.0000000000002820
2. Akaishi T, Sato DK, Nakashima I, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry. 2016;87(4):446-448. doi:10.1136/JNNP-2014-310206
3. Alper G, Petropoulou KA, Fitz CR, Kim Y. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings. Mult Scler. 2011;17(1):74-80. doi:10.1177/1352458510381393
4. Amorim ALM, Cabral NC, Osaku FM, Len CA, Oliveira EML, Terreri MT. Association between demyelinating disease and autoimmune rheumatic disease in a pediatric population. Revista Brasileira de Reumatologia (English Edition). 2017;57(3):224-228. doi:10.1016/j.rbre.2016.09.016
5. Andersen J, Brilot F. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosis. Semin Immunol. 2025;78:101944. doi:10.1016/J.SMIM.2025.101944
6. Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol. 2010;68(5):757-761. doi:10.1002/ANA.22121
7. Arneth B, Kraus J. Laboratory biomarkers of Multiple Sclerosis (MS). Clin Biochem. 2022;99:1-8. doi:10.1016/j.clinbiochem.2021.10.004
8. Auger C, Rovira À. Acute Disseminated Encephalomyelitis and Other Acute Parainfectious Syndromes. Clinical Neuroradiology: The ESNR Textbook. Published online January 1, 2019:787-808. doi:10.1007/978-3-319-68536-6_53
9. Averseng-Peaureaux D, Mizzi M, Colineaux H, et al. Paediatric optic neuritis: factors leading to unfavourable outcome and relapses. Br J Ophthalmol. 2018;102(6):808-813. doi:10.1136/BJOPHTHALMOL-2016-309978
10. Bains SN, Hsieh FH, Rensel MR, et al. Glatiramer acetate: successful desensitization for treatment of multiple sclerosis. Annals of Allergy, Asthma and Immunology. 2010;104(4):321-325. doi:10.1016/j.anai.2009.11.040
11. Banks SA, Morris PP, Chen JJ, et al. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry. 2020;92(4):384-390. doi:10.1136/JNNP-2020-325121
12. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282. doi:10.1016/S1474-4422(22)00431-8
13. Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009;72(3):232-239. doi:10.1212/01.WNL.0000339482.84392.BD
14. Banwell BL. Pediatric multiple sclerosis. Curr Neurol Neurosci Rep. 2004;4(3):245-252. doi:10.1007/S11910-004-0045-1
15. Barnes G, Benjamin S, Bowen JD, et al. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499-505. doi:10.1212/WNL.59.4.499
16. Beck RW, Gal RL. Treatment of Acute Optic Neuritis: A Summary of Findings From the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2008;126(7):994. doi:10.1001/ARCHOPHT.126.7.994
17. Beck RW, Trobe JD. What We Have Learned from the Optic Neuritis Treatment Trial. Ophthalmology. 1995;102(10):1504-1508. doi:10.1016/S0161-6420(95)30839-1
18. Beh SC, Greenberg BM, Frohman T, Frohman EM. Transverse Myelitis. Neurol Clin. 2012;31(1):79. doi:10.1016/J.NCL.2012.09.008
19. Bitnun A, Yeh EA. Acute Flaccid Paralysis and Enteroviral Infections. Curr Infect Dis Rep. 2018;20(9). doi:10.1007/S11908-018-0641-X
20. Boesen MS, Born AP, Jensen PEH, et al. Diagnostic Value of Oligoclonal Bands in Children: A Nationwide Population-Based Cohort Study. Pediatr Neurol. 2019;97:56-63. doi:10.1016/j.pediatrneurol.2019.03.002
21. Boiko A, Vorobeychik G, Paty D, et al. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002;59(7):1006-1010. doi:10.1212/WNL.59.7.1006
22. Boomer JA, Siatkowski RM. Optic neuritis in adults and children. Semin Ophthalmol. 2003;18(4):174-180. doi:10.1080/08820530390895172
23. Borchert M, Liu GT, Pineles S, Waldman AT. Pediatric Optic Neuritis: What Is New. J Neuroophthalmol. 2017;37 Suppl 1(Suppl 1):S14-S22. doi:10.1097/WNO.0000000000000551
24. Bray PF, Luka J, Bray PF, Culp KW, Schlight JP. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology. 1992;42(9):1798-1804. doi:10.1212/WNL.42.9.1798
25. Brodsky M, Nazarian S, Orengo-Nania S, et al. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65(6):727-732. doi:10.1001/ARCHNEUR.65.6.727
26. Brodsky MC, Baker RS, Hamed LM. The Swollen Optic Disc in Childhood. Pediatric Neuro-Ophthalmology. Published online 1996:76-124. doi:10.1007/978-1-4613-8457-1_3
27. Bruijstens AL, Wendel EM, Lechner C, et al. E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology. 2020;29:41-53. doi:10.1016/j.ejpn.2020.10.005
28. Chabas D, Castillo-Trivino T, Mowry EM, Strober JB, Glenn OA, Waubant E. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype? Neurology. 2008;71(14):1090-1093. doi:10.1212/01.WNL.0000326896.66714.AE
29. Chang MY, Pineles SL. Pediatric Optic Neuritis. Semin Pediatr Neurol. 2017;24(2):122-128. doi:10.1016/j.spen.2017.04.004
30. Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95(2):E111-E120. doi:10.1212/WNL.0000000000009758
31. Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin Oligodendrocyte Glycoprotein Antibody–Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018;195:8-15. doi:10.1016/j.ajo.2018.07.020
32. Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016;86(3):245-252. doi:10.1212/WNL.0000000000002283Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130(Pt 5):1235-1243. doi:10.1093/BRAIN/AWM062
33. Cobo-Calvo A, Ruiz A, Rollot F, et al. Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Ann Neurol. 2021;89(1):30-41. doi:10.1002/ANA.25909
34. Cole J, Evans E, Mwangi M, Mar S. Acute Disseminated Encephalomyelitis in Children: An Updated Review Based on Current Diagnostic Criteria. Pediatr Neurol. 2019;100:26-34. doi:10.1016/j.pediatrneurol.2019.06.017
35. Compston A, Coles A. Multiple sclerosis. The Lancet. 2008;372(9648):1502-1517. doi:10.1016/S0140-6736(08)61620-7
36. Costello F, Chen JJ. The role of optical coherence tomography in the diagnosis of afferent visual pathway problems: A neuroophthalmic perspective. Handb Clin Neurol. 2021;178:97-113. doi:10.1016/B978-0-12-821377-3.00007-6
37. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978;3(6):565-566. doi:10.1002/ANA.410030628
38. Dale RC, De Sousa C, Chong WK, Cox TCS, Harding B, Neville BGR. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000;123 Pt 12(12):2407-2422. doi:10.1093/BRAIN/123.12.2407
39. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine. 1992;71(2):59-72. doi:10.1097/00005792-199203000-00001
40. de Mol CL, Wong YYM, van Pelt ED, et al. Incidence and outcome of acquired demyelinating syndromes in Dutch children: update of a nationwide and prospective study. Journal of Neurology 2018 265:6. 2018;265(6):1310-1319. doi:10.1007/S00415-018-8835-6
41. de Mol CL, Wong YYM, van Pelt ED, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Multiple Sclerosis Journal. 2020;26(7):806-814. doi:10.1177/1352458519845112;JOURNAL:JOURNAL:MSJA;ISSUE:ISSUE:DOI
42. Debette S, De Sèze J, Pruvo JP, et al. Long-term outcome of acute and subacute myelopathies. J Neurol. 2009;256(6):980-988. doi:10.1007/S00415-009-5058-X
43. Dică AD, Craiu D, Linca FI, et al. Age-Onset-Related Particularities of Pediatric MS—Understanding the Spectrum: A Tertiary Center Experience. Diseases. 2025;13(7):193. doi:10.3390/DISEASES13070193
44. Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019;26(1):27-40. doi:10.1111/ENE.13819
45. Dubey D, Pittock SJ, Krecke KN, et al. Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. JAMA Neurol. 2019;76(3):301-309. doi:10.1001/JAMANEUROL.2018.4053
46. Dunne K, Hopkins IJ, Shield LK. Acute transverse myelopathy in childhood. Dev Med Child Neurol. 1986;28(2):198-204. doi:10.1111/J.1469-8749.1986.TB03855.X
47. Dutra BG, Da Rocha AJ, Nunes RH, Maia ACM. Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis. Radiographics. 2018;38(1):169-193. doi:10.1148/RG.2018170141
48. El-Dairi MA, Ghasia F, Bhatti MT. Pediatric optic neuritis. Int Ophthalmol Clin. 2012;52(3):29-49. doi:10.1097/IIO.0B013E318259DEC6
49. Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2003;9(3):260-274. doi:10.1191/1352458503MS914OA
50. Ferilli MAN, Paparella R, Morandini I, et al. Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review. Life. 2021;12(1):19. doi:10.3390/LIFE12010019
51. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurology. 2005;4(2):111-121. doi:10.1016/S1474-4422(05)00992-0
52. Gombolay GY, Chitnis T. Pediatric Neuromyelitis Optica Spectrum Disorders. Curr Treat Options Neurol. 2018;20(6). doi:10.1007/S11940-018-0502-9
53. Greenberg BM, Krishnan C, Harder L. New onset transverse myelitis diagnostic accuracy and patient experiences. Mult Scler Relat Disord. 2019;30:42-44. doi:10.1016/J.MSARD.2019.01.046
54. Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology. 2007;68(19):1614-1617. doi:10.1212/01.WNL.0000260970.63493.C8
55. Guier CP, Kaur K, Stokkermans TJ. Optic Neuritis. StatPearls. Published online January 20, 2025. Accessed December 30, 2025. https://www.ncbi.nlm.nih.gov/books/NBK557853/
56. Hacohen Y, Banwell B. Treatment Approaches for MOG-Ab-Associated Demyelination in Children. Curr Treat Options Neurol. 2019;21(1). doi:10.1007/S11940-019-0541-X
57. Hacohen Y, Mankad K, Chong WK, et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology. 2017;89(3):269-278. doi:10.1212/WNL.0000000000004117
58. Hacohen Y, Rossor T, Mankad K, et al. “Leukodystrophy-like” phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease. Dev Med Child Neurol. 2018;60(4):417-423. doi:10.1111/DMCN.13649
59. Helfferich J, Knoester M, Van Leer-Buter CC, et al. Acute flaccid myelitis and enterovirus D68: lessons from the past and present. Eur J Pediatr. 2019;178(9):1305-1315. doi:10.1007/S00431-019-03435-3
60. Hennes EM, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89(9):900-908. doi:10.1212/WNL.0000000000004312
61. Huda S, Whittam D, Jackson R, et al. Predictors of relapse in MOG antibody associated disease: a cohort study. BMJ Open. 2021;11(11):e055392. doi:10.1136/BMJOPEN-2021-055392
62. Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1). doi:10.1186/S12974-018-1144-2
63. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures. J Neurol Sci. 2011;306(1-2):82-90. doi:10.1016/J.JNS.2011.03.038
64. Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1). doi:10.1186/S12974-016-0718-0
65. Jin S, Long Z, Wang W, Jiang B. Hyponatremia in neuromyelitis optica spectrum disorders: Literature review. Acta Neurol Scand. 2018;138(1):4-11. doi:10.1111/ANE.12938
66. Jitprapaikulsan J, Chen JJ, Flanagan EP, et al. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. Ophthalmology. 2018;125(10):1628-1637. doi:10.1016/j.ophtha.2018.03.041
67. Kalra V, Sharma S, Sahu J, et al. Childhood acute transverse myelitis: clinical profile, outcome, and association with antiganglioside antibodies. J Child Neurol. 2009;24(4):466-471. doi:10.1177/0883073808325657
68. Kannan V, Sandweiss AJ, Erickson TA, et al. Fulminant Anti-Myelin Oligodendrocyte Glycoprotein-Associated Cerebral Cortical Encephalitis: Case Series of a Severe Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Phenotype. Pediatr Neurol. 2023;147:36-43. doi:10.1016/J.PEDIATRNEUROL.2023.07.002
69. Kaplin AI, Krishnan C, Deshpande DM, Pardo CA, Kerr DA. Diagnosis and management of acute myelopathies. Neurologist. 2005;11(1):2-18. doi:10.1097/01.NRL.0000149975.39201.0B
70. Keltner JL, Johnson CA, Spurr JO, Beck RW. Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol. 1993;111(2):231-234. doi:10.1001/ARCHOPHT.1993.01090020085029
71. Kennedy C, Carroll FD. Optic Neuritis in Children. AMA Arch Ophthalmol. 1960;63(5):747-755. doi:10.1001/archopht.1960.00950020749001
72. Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165-1173. doi:10.1212/WNL.0000000000001367
73. Komur M, Okuyaz C, Ezgu F, Atici A. A girl with spastic tetraparesis associated with biotinidase deficiency. Eur J Paediatr Neurol. 2011;15(6):551-553. doi:10.1016/J.EJPN.2011.04.012
74. Korinthenberg R, Trollmann R, Felderhoff-Müser U, et al. Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: An evidence- and consensus-based guideline. European Journal of Paediatric Neurology. 2020;25:5-16. doi:10.1016/j.ejpn.2020.01.003
75. Krishnan C, Kaplin AI, Pardo CA, Kerr DA, Keswani SC. Demyelinating disorders: update on transverse myelitis. Curr Neurol Neurosci Rep. 2006;6(3):236-243. doi:10.1007/S11910-006-0011-1
76. Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19(10):1261-1267. doi:10.1177/1352458513484547
77. Langille MM, Rutatangwa A, Francisco C. Pediatric Multiple Sclerosis: A Review. Adv Pediatr. 2019;66:209-229. doi:10.1016/J.YAPD.2019.03.003
78. Lassmann H. Classification of demyelinating diseases at the interface between etiology and pathogenesis. Curr Opin Neurol. 2001;14(3):253-258. doi:10.1097/00019052-200106000-00001
79. Lattanzi S, Cagnetti C, Danni M, Provinciali L, Silvestrini M. Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis. J Neurol. 2017;264(8):1697-1704. doi:10.1007/S00415-017-8505-0
80. Lehman SS, Lavrich JB. Pediatric optic neuritis. Curr Opin Ophthalmol. 2018;29(5):419-422. doi:10.1097/ICU.0000000000000509
81. Lightman S, Mcdonald WI, Bird AC, et al. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain. 1987;110 ( Pt 2)(2):405-414. doi:10.1093/BRAIN/110.2.405
82. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness. J Neuroimmunol. 2006;180(1-2):17-28. doi:10.1016/j.jneuroim.2006.07.006
83. Lopez Chiriboga S, Flanagan EP. Myelitis and Other Autoimmune Myelopathies. Continuum (Minneap Minn). 2021;27(1):62-92. doi:10.1212/CON.0000000000000900
84. López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurol. 2018;75(11):1355-1363. doi:10.1001/JAMANEUROL.2018.1814
85. Love S. Demyelinating diseases. J Clin Pathol. 2006;59(11):1151-1159. doi:10.1136/JCP.2005.031195
86. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-286. doi:10.1212/WNL.0000000000000560
87. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol. 1993;34(2):162-168. doi:10.1002/ANA.410340211
88. Mar S, Lenox J, Benzinger T, Brown S, Noetzel M. Long-term prognosis of pediatric patients with relapsing acute disseminated encephalomyelitis. J Child Neurol. 2010;25(6):681-688. doi:10.1177/0883073809343320
89. Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021;20(9):762-772. doi:10.1016/S1474-4422(21)00218-0
90. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197-2200. doi:10.1212/01.WNL.0000303817.82134.DA
91. Meyer P, Leboucq N, Molinari N, et al. Partial acute transverse myelitis is a predictor of multiple sclerosis in children. Mult Scler. 2014;20(11):1485-1493. doi:10.1177/1352458514526943
92. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6(10):903-912. doi:10.1016/S1474-4422(07)70243-0
93. Miller DH, Newton MR, van der Poel JC, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology. 1988;38(2):175-179. doi:10.1212/WNL.38.2.175
94. Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850-865. doi:10.1016/S1474-4422(25)00270-4
95. Montalvo M, Khattak JF, Redenbaugh V, et al. Acute symptomatic seizures secondary to myelin oligodendrocyte glycoprotein antibody-associated disease. Epilepsia. 2022;63(12):3180-3191. doi:10.1111/EPI.17424
96. Montcuquet A, Collongues N, Papeix C, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler. 2017;23(10):1377-1384. doi:10.1177/1352458516678474
97. Murphy OC, Barreras P, Villabona-Rueda A, Mealy M, Pardo CA. Identification of specific causes of myelopathy in a large cohort of patients initially diagnosed with transverse myelitis. J Neurol Sci. 2022;442. doi:10.1016/j.jns.2022.120425
98. Murphy OC, Messacar K, Benson L, et al. Acute flaccid myelitis: cause, diagnosis, and management. Lancet. 2021;397(10271):334-346. doi:10.1016/S0140-6736(20)32723-9
99. Noland DK, Greenberg BM. Safety and efficacy of plasma exchange in pediatric transverse myelitis. Neurol Clin Pract. 2018;8(4):327-330. doi:10.1212/CPJ.0000000000000480
100. O’Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007;13(2):211-217. doi:10.1038/NM1488
101. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: Clinical aspects. Curr Opin Neurol. 2018;31(6):752-759. doi:10.1097/WCO.0000000000000622
102. Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: A review. Multiple Sclerosis Journal. 2015;21(7):845-853. doi:10.1177/1352458515572406;WEBSITE:WEBSITE:SAGE;ISSUE:ISSUE:DOI
103. Pavone P, Pettoello-Mantovano M, Le Pira A, et al. Acute disseminated encephalomyelitis: a long-term prospective study and meta-analysis. Neuropediatrics. 2010;41(6):246-255. doi:10.1055/S-0031-1271656
104. Pidcock FS, Krishnan C, Crawford TO, Salorio CF, Trovato M, Kerr DA. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology. 2007;68(18):1474-1480. doi:10.1212/01.WNL.0000260609.11357.6F
105. Pidcock FS, Sébire G. What is acute transverse myelitis in children? Demyelinating Disorders of the Central Nervous System in Childhood. Published online January 1, 2011:243-254. doi:10.1017/CBO9780511974373.023
106. Pineles SL, Repka MX, Liu GT, et al. Assessment of Pediatric Optic Neuritis Visual Acuity Outcomes at 6 Months. JAMA Ophthalmol. 2020;138(12):1253-1261. doi:10.1001/JAMAOPHTHALMOL.2020.4231
107. Pohl D, Alper G, Van Haren K, et al. Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome. Neurology. 2016;87(9 Suppl 2):S38-S45. doi:10.1212/WNL.0000000000002825
108. Pohl-Koppe A, Burchett SK, Thiele EA, Hafler DA. Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. J Neuroimmunol. 1998;91(1-2):19-27. doi:10.1016/S0165-5728(98)00125-8
109. Pula JH, MacDonald CJ. Current options for the treatment of optic neuritis. Clin Ophthalmol. 2012;6(1):1211-1223. doi:10.2147/OPTH.S28112
110. Quek AML, McKeon A, Lennon VA, et al. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol. 2012;69(8):1039-1043. doi:10.1001/ARCHNEUROL.2012.249
111. Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016;15(4):307-324. doi:10.1016/j.autrev.2015.12.004
112. Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016;22(4):470-482. doi:10.1177/1352458515593406
113. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603-2613. doi:10.1056/NEJMOA067597
114. Savransky A, Rubstein A, Rios MH, et al. Prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination. Neurology. 2019;93(22):E2065-E2073. doi:10.1212/WNL.0000000000008551
115. Schmalstieg WF, Weinshenker BG. Approach to acute or subacute myelopathy. Neurology. 2010;75(18 Suppl 1). doi:10.1212/WNL.0B013E3181FB3638
116. Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77(24):2128-2134. doi:10.1212/WNL.0B013E31823DC535
117. Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;77(24):2128-2134. doi:10.1212/WNL.0B013E31823DC535
118. Sechi E, Buciuc M, Flanagan EP, et al. Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. Mult Scler Relat Disord. 2021;47. doi:10.1016/j.msard.2020.102638
119. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019-1032. doi:10.1111/J.1468-1331.2010.03066.X
120. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214-1228. doi:10.1016/S0140-6736(21)00517-1
121. Simone CG, Emmady PD. Transverse Myelitis. StatPearls. Published online November 15, 2022. Accessed December 26, 2025. https://www.ncbi.nlm.nih.gov/books/NBK559302/
122. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683-747. doi:10.1146/ANNUREV.IMMUNOL.23.021704.115707
123. Spatola M, Chuquisana O, Jung W, et al. Humoral signatures of MOG-antibody-associated disease track with age and disease activity. Cell Rep Med. 2023;4(2):100913. doi:10.1016/j.xcrm.2022.100913
124. Stonehouse M, Gupte G, Wassmer E, Whitehouse WP. Acute disseminated encephalomyelitis: recognition in the hands of general paediatricians. Arch Dis Child. 2003;88(2):122-124. doi:10.1136/ADC.88.2.122
125. Tekavčič-Pompe M, Stirn-Kranjc B, Brecelj J. Optic neuritis in children--clinical and electrophysiological follow-up. Doc Ophthalmol. 2003;107(3):261-270. doi:10.1023/B:DOOP.0000005335.28820.05
126. Tenembaum S, Chitnis T, Nakashima I, et al. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology. 2016;87(9 Suppl 2):S59-S66. doi:10.1212/WNL.0000000000002824
127. Tenembaum S, Chitnis T, Ness J, Hahn JS. Acute disseminated encephalomyelitis. Neurology. 2007;68(16 Suppl 2). doi:10.1212/01.WNL.0000259404.51352.7F
128. Thomas T, Branson HM, Verhey LH, et al. The demographic, clinical, and magnetic resonance imaging (MRI) features of transverse myelitis in children. J Child Neurol. 2012;27(1):11-21. doi:10.1177/0883073811420495
129. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. doi:10.1016/S1474-4422(17)30470-2
130. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. The Lancet. 2018;391(10130):1622-1636. doi:10.1016/S0140-6736(18)30481-1
131. Tobin WO, Weinshenker BG, Lucchinetti CF. Longitudinally extensive transverse myelitis. Curr Opin Neurol. 2014;27(3):279-289. doi:10.1097/WCO.0000000000000093
132. Transverse Myelitis - Symptoms, Causes, Treatment | NORD. Accessed December 27, 2025. https://rarediseases.org/rare-diseases/transverse-myelitis/
133. Trewin BP, Brilot F, Reddel SW, Dale RC, Ramanathan S. MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. Autoimmun Rev. 2025;24(1):103693. doi:10.1016/J.AUTREV.2024.103693
134. Waldman A, Ness J, Pohl D, et al. Pediatric multiple sclerosis: Clinical features and outcome. Neurology. 2016;87(9 Suppl 2):S74. doi:10.1212/WNL.0000000000003028
135. Waldman AT, Gorman MP, Rensel MR, et al. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol. 2011;26(6):675-682. doi:10.1177/0883073810395141
136. Waldman AT, Stull LB, Galetta SL, Balcer LJ, Liu GT. Pediatric optic neuritis and risk of multiple sclerosis: Meta-analysis of observational studies. Journal of AAPOS. 2011;15(5):441-446. doi:10.1016/j.jaapos.2011.05.020
137. Wang C, Greenberg B. Clinical Approach to Pediatric Transverse Myelitis, Neuromyelitis Optica Spectrum Disorder and Acute Flaccid Myelitis. Children (Basel). 2019;6(5). doi:10.3390/CHILDREN6050070
138. Wang CX. Assessment and Management of Acute Disseminated Encephalomyelitis (ADEM) in the Pediatric Patient. Paediatr Drugs. 2021;23(3):213. doi:10.1007/S40272-021-00441-7
139. Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20(8):653-670. doi:10.1016/S1474-4422(21)00095-8
140. Waubant E, Chabas D, Okuda DT, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009;66(8):967-971. doi:10.1001/ARCHNEUROL.2009.135
141. Weidauer S, Wagner M, Nichtweiß M. Magnetic Resonance Imaging and Clinical Features in Acute and Subacute Myelopathies. Clin Neuroradiol. 2017;27(4):417-433. doi:10.1007/S00062-017-0604-X
142. West TW, Hess C, Cree BAC. Acute transverse myelitis: Demyelinating, inflammatory, and infectious myelopathies. Semin Neurol. 2012;32(2):97-113. doi:10.1055/S-0032-1322586
143. West TW. Transverse Myelitis — a Review of the Presentation, Diagnosis, and Initial Management. Discov Med. 2013;16(88):167-177.
144. Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology. 2006;67(2):258-262. doi:10.1212/01.WNL.0000224757.69746.FB
145. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729;JOURNAL:JOURNAL:WNL;WGROUP:STRING:PUBLICATION
146. Wingerchuk DM, Lucchinetti CF. Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2022;387(7):631-639. doi:10.1056/NEJMRA1904655
147. Wingerchuk DM. Immune-Mediated Myelopathies. Continuum (Minneap Minn). 2018;24(2, Spinal Cord Disorders):497-522. doi:10.1212/CON.0000000000000582
148. Wolf VL, Lupo PJ, Lotze TE. Pediatric acute transverse myelitis overview and differential diagnosis. J Child Neurol. 2012;27(11):1426-1436. doi:10.1177/0883073812452916
149. Xiong CH, Yan Y, Liao Z, et al. Epidemiological characteristics of acute disseminated encephalomyelitis in Nanchang, China: a retrospective study. BMC Public Health 2014 14:1. 2014;14(1):111-. doi:10.1186/1471-2458-14-111
150. Yamaguchi Y, Torisu H, Kira R, et al. A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology. 2016;87(19):2006-2015. doi:10.1212/WNL.0000000000003318;PAGE:STRING:ARTICLE/CHAPTER
151. Yaregal S, Bekele N, Gebrewold Y, Tadesse A. Neuromyelitis Optica Spectrum Disorder: A Case Report. Published online 2021. doi:10.2147/IMCRJ.S334362
152. Yeshokumar AK, Narula S, Banwell B. Pediatric multiple sclerosis. Curr Opin Neurol. 2017;30(3):216-221. doi:10.1097/WCO.0000000000000452
153. Yiu EM, Kornberg AJ, Ryan MM, Coleman LT, Mackay MT. Acute transverse myelitis and acute disseminated encephalomyelitis in childhood: spectrum or separate entities? J Child Neurol. 2009;24(3):287-296. doi:10.1177/0883073808323522